• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名接受康复期血浆治疗的 COVID-19 感染淋巴瘤患者出现病毒长时间脱落。

Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma.

作者信息

Karataş Ayşe, İnkaya Ahmet Çağkan, Demiroğlu Haluk, Aksu Salih, Haziyev Tahmaz, Çınar Olgu Erkin, Alp Alpaslan, Uzun Ömrüm, Sayınalp Nilgün, Göker Hakan

机构信息

Hacettepe University Faculty of Medicine, Department of Internal Medicine, Hematology Unit, Ankara, Turkey.

Hacettepe University Faculty of Medicine, Department of Infectious Diseases, Ankara, Turkey.

出版信息

Transfus Apher Sci. 2020 Oct;59(5):102871. doi: 10.1016/j.transci.2020.102871. Epub 2020 Jul 3.

DOI:10.1016/j.transci.2020.102871
PMID:32694044
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7333597/
Abstract

Acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first identified in Wuhan, China; and spread all over the world. Reverse-transcription polymerase chain reaction (RT-PCR) test for SARS-CoV-2 usually returns to negative in 20 days post-infection, but prolonged positivity has been reported up to 63 days. A case whose viral shedding lasted 60 days is reported from China. Herein we report a patient with a history of autologous stem cell transplantation (ASCT) for lymphoma whose RT-PCR test remained positive for SARS-CoV-2 for 74 days. The prolonged RT-PCR positivity, despite convalescent plasma infusion, may suggest that the given antibodies may be ineffective in terms of viral clearance. In patients with hematological malignancies or immunosuppression, such as ASCT, may lead to prolonged viral shedding, and strict isolation is warranted for long-term SARS-CoV-2 infection control.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)最初在中国武汉被发现,并传播至全球。SARS-CoV-2的逆转录聚合酶链反应(RT-PCR)检测通常在感染后20天转为阴性,但也有报道称阳性结果会持续长达63天。中国报告了1例病毒脱落持续60天的病例。在此,我们报告1例因淋巴瘤接受自体干细胞移植(ASCT)的患者,其SARS-CoV-2的RT-PCR检测在74天内一直呈阳性。尽管输注了康复期血浆,但RT-PCR阳性结果持续时间延长,这可能表明所给予的抗体在病毒清除方面可能无效。对于血液系统恶性肿瘤或免疫抑制患者,如接受ASCT的患者,可能会导致病毒脱落时间延长,因此有必要进行严格隔离以长期控制SARS-CoV-2感染。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/635b/7333597/e64fbeb32d11/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/635b/7333597/e64fbeb32d11/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/635b/7333597/e64fbeb32d11/gr1_lrg.jpg

相似文献

1
Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma.一名接受康复期血浆治疗的 COVID-19 感染淋巴瘤患者出现病毒长时间脱落。
Transfus Apher Sci. 2020 Oct;59(5):102871. doi: 10.1016/j.transci.2020.102871. Epub 2020 Jul 3.
2
Persistent viral RNA shedding after COVID-19 symptom resolution in older convalescent plasma donors.COVID-19 症状缓解后老年恢复期血浆供者持续的病毒 RNA 脱落。
Transfusion. 2020 Oct;60(10):2189-2191. doi: 10.1111/trf.15927. Epub 2020 Jun 24.
3
Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019.新冠肺炎患者恢复期血浆疗法对病毒脱落和生存的影响。
J Infect Dis. 2020 Jun 16;222(1):38-43. doi: 10.1093/infdis/jiaa228.
4
Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient.免疫功能低下患者中 SARS-CoV-2 的病毒持续排出。
J Infect Chemother. 2021 Feb;27(2):387-389. doi: 10.1016/j.jiac.2020.12.001. Epub 2020 Dec 4.
5
Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study.SARS-CoV-2 RNA 持续阳性的患者从恢复期血浆治疗中获益:一项回顾性研究。
Virol Sin. 2020 Dec;35(6):768-775. doi: 10.1007/s12250-020-00281-8. Epub 2020 Aug 31.
6
Prolonged SARS-Cov-2 shedding with rapid IgG antibody decay in a COVID-19 patient: A case report.SARS-CoV-2 持续排出伴 COVID-19 患者 IgG 抗体快速衰减:一例报告。
J Clin Lab Anal. 2021 Nov;35(11):e24002. doi: 10.1002/jcla.24002. Epub 2021 Sep 15.
7
Three COVID-19 cases with a long-term viral shedding period in Tunisia.突尼斯出现三例新冠病毒长期排毒病例。
Pan Afr Med J. 2020 Jul 16;35(Suppl 2):117. doi: 10.11604/pamj.supp.2020.35.2.24950. eCollection 2020.
8
Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors.SARS-CoV-2 鼻咽拭子 PCR 阳性在 COVID-19 恢复期血浆供者中的持续存在。
Transfusion. 2020 Dec;60(12):2962-2968. doi: 10.1111/trf.16015. Epub 2020 Aug 24.
9
A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.2020 年 2 月至 3 月,中国武汉的 2 家中心对 24 例 COVID-19 肺炎患者进行了恢复期血浆治疗效果的回顾性研究。
Med Sci Monit. 2020 Dec 2;26:e928755. doi: 10.12659/MSM.928755.
10
Risk factors for prolonged virus shedding of respiratory tract and fecal in adults with severe acute respiratory syndrome coronavirus-2 infection.成人严重急性呼吸综合征冠状病毒 2 感染患者呼吸道和粪便病毒持续排出的危险因素。
J Clin Lab Anal. 2021 Sep;35(9):e23923. doi: 10.1002/jcla.23923. Epub 2021 Aug 13.

引用本文的文献

1
Severe acute respiratory syndrome coronavirus 2 infection in patients with hematological malignancies in the Omicron era: Respiratory failure, need for mechanical ventilation and mortality in seronegative and seropositive patients.奥密克戎时代血液系统恶性肿瘤患者的严重急性呼吸综合征冠状病毒2感染:血清阴性和血清阳性患者的呼吸衰竭、机械通气需求及死亡率
EJHaem. 2024 Apr 9;5(3):505-515. doi: 10.1002/jha2.867. eCollection 2024 Jun.
2
Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation.在开始抗逆转录病毒治疗(ART)后,HIV 疾病晚期患者体内持续的 SARS-CoV-2 清除与中和抗体的增加有关。
Nat Commun. 2024 Mar 15;15(1):2360. doi: 10.1038/s41467-024-46673-2.
3

本文引用的文献

1
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.恢复期血浆疗法对重症和危及生命的 COVID-19 患者临床改善时间的影响:一项随机临床试验。
JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044.
2
SARS-CoV-2: The viral shedding vs infectivity dilemma.严重急性呼吸综合征冠状病毒2:病毒脱落与传染性的困境。
Infect Dis Health. 2020 Aug;25(3):210-215. doi: 10.1016/j.idh.2020.05.002. Epub 2020 May 20.
3
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Characteristics and Outcomes of Stem Cell Transplant Patients during the COVID-19 Era: A Systematic Review and Meta-Analysis.
COVID-19 大流行期间干细胞移植患者的特征与结局:一项系统综述和荟萃分析
Healthcare (Basel). 2024 Feb 23;12(5):530. doi: 10.3390/healthcare12050530.
4
Recurrent COVID-19 Infection in a Refractory/Classical Hodgkin's Lymphoma Patient Undergoing Autologous Stem Cell Transplantation: A Case Report.一名正在接受自体干细胞移植的难治性/经典型霍奇金淋巴瘤患者发生复发性新型冠状病毒肺炎感染:病例报告
Cureus. 2023 Oct 13;15(10):e46950. doi: 10.7759/cureus.46950. eCollection 2023 Oct.
5
Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma.在一例接受恶性淋巴瘤B细胞清除免疫治疗后出现长时间新冠病毒感染的病例中,使用瑞德西韦和恩西他韦进行成功的双重抗病毒治疗。
IDCases. 2023 Aug 30;34:e01890. doi: 10.1016/j.idcr.2023.e01890. eCollection 2023.
6
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗:一项实时系统评价。
Cochrane Database Syst Rev. 2023 May 10;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub6.
7
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗:一项实时系统评价。
Cochrane Database Syst Rev. 2023 Feb 1;2(2):CD013600. doi: 10.1002/14651858.CD013600.pub5.
8
COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.COVID-19 恢复期血浆治疗免疫功能低下患者:系统评价和荟萃分析。
JAMA Netw Open. 2023 Jan 3;6(1):e2250647. doi: 10.1001/jamanetworkopen.2022.50647.
9
SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19.SARS-CoV-2 在长期 COVID-19 期间逃避细胞毒性 T 细胞。
Nat Commun. 2023 Jan 10;14(1):149. doi: 10.1038/s41467-022-34033-x.
10
Effectiveness of Convalescent Plasma Therapy in COVID-19 Patients with Hematological Malignancies: A Systematic Review.恢复期血浆疗法对 COVID-19 合并血液系统恶性肿瘤患者的疗效:一项系统评价。
Hematol Rep. 2022 Dec 12;14(4):377-388. doi: 10.3390/hematolrep14040052.
COVID-19 对癌症患者的临床影响(CCC19):一项队列研究。
Lancet. 2020 Jun 20;395(10241):1907-1918. doi: 10.1016/S0140-6736(20)31187-9. Epub 2020 May 28.
4
Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma.治疗新型冠状病毒肺炎(COVID-19)患者的恢复期血浆。
Am J Pathol. 2020 Aug;190(8):1680-1690. doi: 10.1016/j.ajpath.2020.05.014. Epub 2020 May 27.
5
Case Report: Viral Shedding for 60 Days in a Woman with COVID-19.病例报告:一名 COVID-19 女性患者病毒脱落 60 天。
Am J Trop Med Hyg. 2020 Jun;102(6):1210-1213. doi: 10.4269/ajtmh.20-0275.
6
Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China.新型冠状病毒肺炎合并免疫抑制的肾移植受者肺炎:中国武汉 10 例确诊病例总结
Eur Urol. 2020 Jun;77(6):748-754. doi: 10.1016/j.eururo.2020.03.039. Epub 2020 Apr 18.
7
COVID-19 and immunomodulation in IBD.COVID-19 与 IBD 中的免疫调节。
Gut. 2020 Jul;69(7):1335-1342. doi: 10.1136/gutjnl-2020-321269. Epub 2020 Apr 17.
8
Prolonged virus shedding even after seroconversion in a patient with COVID-19.一名新冠肺炎患者在血清转化后仍长期存在病毒脱落现象。
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.03.063. Epub 2020 Apr 10.
9
Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?新冠病毒感染中针对过度炎症反应的免疫抑制:一把双刃剑?
Lancet. 2020 Apr 4;395(10230):1111. doi: 10.1016/S0140-6736(20)30691-7. Epub 2020 Mar 24.
10
Convalescent plasma as a potential therapy for COVID-19.康复期血浆作为治疗新冠肺炎的一种潜在疗法。
Lancet Infect Dis. 2020 Apr;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9. Epub 2020 Feb 27.